Rapamycin is employed as an immunosuppressant following organ transplant and, in patients with hepatocellular carcinoma, to inhibit cancer cell regrowth following liver surgery. Preconditioning the liver with rapamycin to induce the expression of antioxidant enzymes is a potential strategy to reduce ischemia reperfusion (IR) injury. However, pre-treatment with rapamycin inhibits bile flow, especially following ischemia. The aim was to investigate the mechanisms involved in this inhibition. In a rat model of segmental hepatic ischemia and reperfusion, acute administration of rapamycin by intravenous injection did not inhibit the basal rate of bile flow. Pre-treatment of rats with rapamycin for 24 h by intraperitoneal injection inhibited the expression of mRNA encoding the sinusoidal influx transporters Ntcp, Oatp1 and 2 and the canalicular efflux transporter Bsep, and increased expression of canalicular Mrp2. Dose-response curves for the actions of rapamycin on the expression of Bsep and Ntcp in cultured rat hepatocytes were biphasic, and monophasic for effects on Oatp1. In cultured tumorigenic H4IIE liver cells, several bile acid transporters were not expressed, or were expressed at very low levels compared to hepatocytes. In H4IIE cells, rapamycin increased expression of Ntcp, Oatp1 and Mrp2, but decreased expression of Oatp2. It is concluded that the inhibition of bile flow recovery following ischemia observed in rapamycin-treated livers is principally due to inhibition of the expression of sinusoidal bile acid transporters. Moreover, in tumorigenic liver tissue the contribution of tumorigenic hepatocytes to total liver bile flow is likely to be small and is unlikely to be greatly affected by rapamycin.
Introduction
Rapamycin (sirolimus), or analogues of rapamycin such as everolimus, are presently employed as an immunosuppressant following liver transplant for end stage liver disease, and following other organ transplants (Cholongitas et al., 2014; Ferreiro et al., 2014; Ghazal et al., 2017; Hamdani et al., 2017; Schnitzbauer et al., 2010; Soll and Clavien, 2011; Toso et al., 2010) . Rapamycin inhibits mTORC1 kinase, leading to, among other consequences, inhibition of cell proliferation (Dibble and Cantley, 2015) . In patients with hepatocellular carcinoma (HCC), rapamycin or an analogue is administered after liver transplants to inhibit cancer cell regrowth (Cholongitas et al., 2014; Sanchez Antolin et al., 2011; Soll and Clavien, 2011; Thorat et al., 2017; Toso et al., 2010; Zhang et al., 2018) . Moreover, rapamycin and other mTORC1 inhibitors are being clinically trialed for the treatment of HCC patients for whom liver resection or liver transplant is not an option (Huang et al., 2015; Park et al., 2016; Zhu et al., 2014) . Recent studies have provided evidence that pre-treatment with the rapamycin analogue everolimus can protect the liver from IR injury (Lee et al., 2016) .
The actions of rapamycin on the liver are complex, and there are a number of potentially detrimental side effects in patients treated with rapamycin (Cholongitas et al., 2014; Geissler et al., 2016; Sanchez Antolin et al., 2011; Schnitzbauer et al., 2010; Toso et al., 2010) . Several previous studies have shown that rapamycin inhibits the basal rate of bile flow and the recovery of bile flow following IR (Bramow et al., 2001; Deters et al., 2002 Deters et al., , 2001 Fehrenbach et al., 2003; Oswald et al., 2010; Picard et al., 2011) . The latter is associated with impaired recovery of the liver following a liver transplant (Lo et al., 2018; Shiffman et al., 1991) . Treatment of the liver with rapamycin and its analogues can also lead to drug-induced cholestasis under a variety of conditions (Bramow et al., 2001; Dandel et al., 2010; Pantano et al., 2010) . The mechanisms by which rapamycin inhibits bile flow and induces cholestasis are not well understood. Two likely mechanisms are the binding of rapamycin to bile acid transporters leading to competitive or allosteric inhibition of bile acid transporter activity and decreased expression of bile acid transporter proteins (Bramow et al., 2001; Deters et al., 2002 Deters et al., , 2001 Fehrenbach et al., 2003; Oswald et al., 2010; Picard et al., 2011) .
In our previous studies of surgical and pharmacological strategies which can reduce liver IR injury, we have used the rate of bile flow, measured during the initial period of reperfusion following ischemia, as an indicator or liver damage (Nieuwenhuijs et al., 2007; Peters et al., 2009; Schiesser et al., 2009) . Bile flow recovery, monitored immediately following ischemia, has been used in many laboratories and clinics to assess the severity of IR injury following IR in liver resection and in liver transplant surgery (Accatino et al., 2003; Bilzer et al., 2002; Fusai et al., 2005; Koeppel et al., 1998; Legido-Quigley et al., 2011; Lu et al., 2014; Ninomiya et al., 2002) . Our studies employed an established rat model of segmental hepatic ischemia involving 30-60 min ischemia and 45-120 min reperfusion. While little liver injury, as assessed by the release of alanine aminotransaminase, aspartate aminotransaminase and lactate dehydrogenase, or by histological analysis, is evident at the end of the reperfusion period, IR causes a substantial reduction in bile flow recovery following ischemia (Nieuwenhuijs et al., 2007; Schiesser et al., 2009) . Moreover, ischemia preconditioning and intermittent ischemia greatly improve bile flow recovery, indicating that these strategies also reduce the likelihood of IR injury (Nieuwenhuijs et al., 2007; Peters et al., 2009; Schiesser et al., 2009) . We found that pre-treatment with rapamycin induces expression of the antioxidant enzymes heme oxygenase-1 and peroxiredoxin-1 in liver, suggesting that rapamycin may protect the liver against ischemia reperfusion (IR) injury by reducing reactive oxygen species. However, we also found that pre-treatment with rapamycin reduces the basal rate of bile flow and bile flow recovery following IR (Kist et al., 2012) .
The aim of this study was to further investigate the contribution of allosteric inhibition of bile acid transporter activity and decreased expression of bile acid transporter proteins to the inhibition of basal bile flow and the inhibition of bile flow recovery following liver ischemia observed in livers pre-treated with rapamycin. Since, in the potential treatment of HCC patients with rapamycin and other mTORC1 inhibitors, tumorigenic as well as normal liver tissue would be exposed to the drug, the effect of rapamycin on the expression of bile acid transporters in tumorigenic liver cells was also investigated.
Materials and methods

Animals
Male Sprague Dawley and Zucker rats, aged between 8 and 14 weeks, and weighing 270-420 g were housed and bred in a controlled environment with a 12 h light-dark cycle, with access to food and water ad libitum. Animals received humane care, and the experimental protocols were conducted according to the criteria outlined in the "Australian Code of Practice for the Care and Use of Animals for Scientific Purposes" (National Health and Medical Research Council of Australia).
2.2. Surgical procedures for ischemia and reperfusion and measurement of the rates of bile flow and blood concentrations of rapamycin An established rat model of segmental (60-70%) hepatic ischemia and reperfusion was employed (Hasselgren et al., 1982) (Fig. 1) . The bilateral median and left lateral liver lobes of Sprague Dawley rats were made ischemic, whereas the right lateral and caudate lobes remained non-ischemic. Surgical procedures, the measurement of bile flow, collection of liver samples from both ischemic and non-ischemic liver lobes, and the measurement of blood concentrations of rapamycin were all conducted as described previously (Kist et al., 2012; Peters et al., 2009) . All experiments were performed under general anesthesia with isoflurane gas inhalation. Anesthesia was established by installing an inhalation mouthpiece through which a 3% (v/v) isoflurane flow was combined with O 2 0.6 L/min and N 2 O 0.4 L/min. The isoflurane flow was lowered to 2-1.75% throughout the procedure. Anesthesia was maintained during the periods of ischemia and reperfusion. At the end of the reperfusion period, the rat was killed by exsanguination under anesthesia. While there is evidence that volatile anesthetics such as isofluorane and sevofluorane give some protection against IR injury, recent studies have shown that ischemic preconditioning can give substantial protection against IR injury over and above any provided by the volatile anesthetic itself (Bedirli et al., 2008; Jeong et al., 2017) . These results indicate that, while isofluorane may have some effect on the progression of IR and recovery of the liver from IR, this is likely small, and in the present study is a constant factor in all experiments.
A dissecting microscope was used for cannulation of the bile duct. First, the bile duct was prepared proximally from the bifurcation where the bile ducts from the superior and inferior lobes join. Just above the level of the head of the pancreas, the bile duct was incised with small scissors and a silicon cannula (OD 0.8 mm, ID 0.5 mm, Biocorp Australia Pty. Ltd.) was inserted and secured with ligatures. The intestines were placed back into the abdominal cavity for the rest of the experiment. After 20 min of baseline bile flow had been collected, segmental hepatic ischemia was induced. An atraumatic microvascular clamp (micro serrefine, 10 mm long × 2 mm wide, Fine Science Tools, Foster City, CA, U.S.A.) was placed on the portal vein and hepatic artery leading towards the left lateral and bilateral median lobes. The liver was inspected for collateral vessels that might prevent complete ischemia. During clamping, complete ischemia was verified by checking colour, capillary refill and decline of bile flow to less than 5% of baseline flow. When collateral vessels were found or if insufficient ischemia was detected otherwise, the experiment was discontinued, and the samples obtained were not used for analysis. Clamping was applied for the times indicated in Fig. 1 , after which the micro-clamp was removed. After removal of the micro-clamp, bile flow was measured for another for the time period indicted in Fig. 1. 
Rapamycin solutions
Stock solutions of rapamycin (LC Laboratories, MA, U.S.A.) were prepared in filter-sterilized absolute ethanol and stored at − 20°C. For administration to rats, the rapamycin stock solution was diluted in filter-sterilized phosphate-buffered saline (137 mM NaCl, 10 mM sodium phosphate, 2.7 mM KCl, pH 7.4) to create a 2.5 mg/ml working solution. Before use, solutions of rapamycin and vehicle were pre-heated to 45C and mixed well.
Rapamycin was administered to rats intra-operatively by i.v. injection into the inferior vena cava using a 1 ml syringe and a 26 G 1⁄2 needle, while the rat was anesthetized with isofluorane as described above. For pre-treatment with rapamycin, the drug or vehicle was administered to rats by i.p. injection under isofluorane anesthesia, conducted as described above, and maintained for a short period of time. The doses employed were 2.5 (i.v. injection) and 4 (i.p. injection) mg/ kg body weight, as indicated in the legends to Figures. For the administration of rapamycin to hepatocytes and H4IIE liver cells in culture, a stock solution of the drug was prepared in ethanol (Kist et al., 2012) . The maximum final concentration of ethanol in cell cultures was 0.2% (v/v) . Oltipraz (LKT Laboratories, Inc. USA) was dissolved in dimethyl sulphoxide (DMSO) to create a working solution of 1 mg/ml, and then diluted in Dulbecco's Modified Eagle's Medium (DMEM) to give the final concentrations indicated in the figures.
Isolation and culture of hepatocytes
Hepatocytes were isolated from lean Zucker rats by collagenase digestion, as described previously (Aromataris et al., 2006; Castro et al., 2009) , and cultured in T-25 flasks in 5% (v/v) CO 2 in air at 37°C in the presence of 8 ml of DMEM containing penicillin (100 U/ml), streptomycin (100 μg/ml) and 10% (v/v) fetal bovine serum (FBS) (Trace, Melbourne, Australia). After 4 h, when the cells had attached to the flask, the medium was replaced with fresh DMEM (8 ml) containing FBS, penicillin and streptomycin. The cells were then incubated for 24 h before the administration of rapamycin or vehicle. After a further incubation for 36 h, the medium was removed, and the cells harvested for the extraction of RNA.
Culture of tumorigenic H4IIE rat liver cells
Cultures of H4IIE rat liver cells (CRL-1548 cell line, ATCC, Rockville, MD, USA) (Evans and Kovacs, 1977) were maintained in 75 cm 2 sterile flasks in DMEM, supplemented with 10% (v/v) FBS, penicillin (100 U/ml), streptomycin (100 μg/ml) and10 mM HEPES in 5% (v/v) CO 2 (pH 7.4) at 37°C (Wilson et al., 2015) . The cells were used for a maximum of 25-30 passages.
To determine the effects of rapamycin and other agents on the expression of bile acid transporters, H4IIE cells were sub-cultured into T-25 flasks (seeded with 2.5 × 10 6 cells). After 24 h, the medium was replaced with fresh DMEM (8 ml) containing FBS, penicillin and streptomycin, and rapamycin, oltipraz or vehicle was administered at the concentrations indicated in the Figures. After a further incubation for 36 h, the medium was removed, and the cells harvested for the extraction of RNA. Differentiation of H4IIE rat liver cells was achieved by culturing the cells in T-25 flasks in DMEM supplemented with FBS (10% v/v), penicillin (100 U/ml), streptomycin (100 µg/ml), insulin (100 nM final concentration) and dexamethasone (100 nM final concentration) for 5-10 days at 37°C in 5% (v/v) CO 2 (pH 7.4), as described previously (Jones et al., 2011) . The degree of cell differentiation was assessed morphologically using light microscopy. Compared to undifferentiated cells, differentiated H4IIE cells were larger, more round in shape, exhibited a more clearly-defined nucleus, and glittered more noticeably, indicating the presence of lipid droplets. We have previously shown that incubation of H4IIE cells with insulin and dexamethasone increases the expression of ATP-responsive P2Y receptors on the plasma membrane (Jones et al., 2011) . Studies by others on the effects of insulin and dexamethasone on H4IIE cells have shown that the actions of these agents over several days include an increase the activity and amount of phosphofructokinase, expression of insulin-like growth factor receptor-1, and expression of the transcription factor c-fos (Messina et al., 1992; Vargas et al., 1994; Zahradka et al., 1998 ).
Extraction of RNA and quantitative PCR
The extraction of RNA from frozen liver sections derived from both ischemic and non-ischemic liver lobes, and from cultured hepatocytes and H4IIE rat liver cells, synthesis of cDNA, and semi-quantitative and quantitative PCR (qPCR) were conducted as described previously (Kist et al., 2012; Llacuna et al., 2009; Wilson et al., 2011) . Quantitative PCR was conducted using probe-based strategies, β-actin as reference RNA, a Rotor-Gene 3000 (Corbett) and the ΔΔCT method (Wilson et al., 2011) .
Primers and fluorescent probes were synthesized by Geneworks, Adelaide, Australia, based on published sequences (Table 1) . Triplicate incubations were conducted for each experimental condition. For qPCR, the cDNA from each RNA extract derived from liver tissue or cells in culture was amplified in triplicate, and the mean value determined.
Quantitative PCR was employed as the principle technique for measurement of the expression of bile acid transporters because it can offer more precise quantitation than measurement of protein expression by western blot and can more readily be applied to the assay of multiple samples generated in dose-response experiments. Other studies of bile acid transporter expression have shown a good correlation between results obtained using qPCR and those obtained using western blot (Liu et al., 2017; Weerachayaphorn et al., 2009 Weerachayaphorn et al., , 2012 .
Western blots
Western bots were performed as described previously (Wilson et al., 2015 (Wilson et al., , 2011 . Proteins were separated by electrophoresis on a stain-free Bio-Rad AnyKD gel (mini gel, 10 wells per gel) (30 μg protein per lane) and transferred to PVDF membranes using a Trans-Blot ® Turbo™ RTA Mini LF PVDF Transfer Kit. Stain-Free imaging of total protein and chemiluminescent imaging of the protein of interest on the PVDF membrane were conducted using a Bio-Rad Gel-Doc EZ Imager. Band intensities were quantified using Image Studio Lite software (LI-COR Biosciences). Local background was subtracted, and the value for a given band (Oatp2 or Mrp2) was normalized to the total protein on the membrane (Colella et al., 2012; Gilda and Gomes, 2013; Gurtler et al., 2013; Wilson et al., 2016) . The origins and dilutions of the primary and secondary antibodies employed were as follows: for the detection of Oatp2, mouse monoclonal (Oatp2 (A-2) sc-376424, Santa Cruz Biotechnology, Dallas, Texas, USA) 1:100 with secondary antibody Donkey anti mouse-HRP 1:1000; for the detection of Mrp2, mouse monoclonal (Mrp2 (M2III-5) sc-59611, Santa Cruz Biotechnology) 1:10, with secondary antibody Donkey anti mouse-HRP 1:1000.
Statistical analysis
Results are expressed as means ± S.E.M. Values for bile flow between groups were compared using independent Student's t-test. Mean values within groups were compared using a paired samples t-test. To determine linear correlation estimates, Pearson correlation coefficients were computed for the rapamycin blood concentration and the bile flow recovery rate during reperfusion following ischemia. For the analysis of relative expression of mRNA, Student's t-test or ANOVA followed by Post Hoc Tukey's test was used. Means of two groups were compared using Student's t-test. When the treatment groups were more than two, ANOVA was used for comparison the mean value. Statistical significance was considered when P values were less than 0.05. Equations were fitted to the experimental data in dose-response curves using Graphpad Prism 5 software.
Results
Effects of rapamycin on the basal rate of bile flow and on bile flow recovery following ischemia
We previously found that 24 h pre-treatment of rats with rapamycin, administered by i.p. injection, inhibits both the basal rate of bile flow Fig. 1 . Schematic representation of the established rat model of segmental hepatic ischemia and reperfusion and bile collection employed in the present study (A) and the three protocols employed for the administration of rapamycin to rat liver (B-D). A) In the rat model of segmental hepatic ischemia, the bilateral median and left lateral lobes were made ischemic while the right lateral and caudate lobes remained non-ischemic (Hasselgren et al., 1982) . This gives about 60-70% liver ischemia. Locations of the common bile duct (1), the bile duct cannula (4) and surrounding ligature (5), the hepatic artery (2), portal vein (3), and the position of the microvascular clamp (6) are indicated schematically. B) Rapamycin administered (i.v) 50 min before initiating ischemia. C) Rapamycin administered (i.v) immediately before measurement of baseline bile flow. D) Pre-treatment with rapamycin, in which the drug was administered (i.p) 24 h before initiating ischemia. and bile flow recovery following liver IR (Kist et al., 2012) . In these experiments, the blood concentration of rapamycin at the end of the 24 h pre-treatment period was about 25 nM (Kist et al., 2012) . To test whether the effects of rapamycin on bile flow are due to inhibition of the activity of bile acid transporters following liver ischemia, either by competitive inhibition as a substrate or by non-competitive or allosteric inhibition, we used the same rat model of segmental hepatic ischemia in which the bilateral median and left lateral lobes were made ischemic. The right lateral and caudate lobes were perfused normally. The drug was administered by i.v. injection to the vena cava 50 min before clamping of the portal triad (shown schematically in Fig. 1A, B) . We have previously shown, that in this rat liver model of the acute effects of IR, little liver injury, as assessed by the release of alanine aminotransaminase, aspartate aminotransaminase and lactate dehydrogenase, or histologically, is evident at the end of the reperfusion period (Kist et al., 2012; Nieuwenhuijs et al., 2007; Schiesser et al., 2009 ). However, IR causes a substantial reduction in bile flow recovery following IR which has been used as a measure of the degree of IR injury (Nieuwenhuijs et al., 2007; Schiesser et al., 2009) .
The rate of bile flow recovery in livers treated with rapamycin was about 33% lower than that in livers treated with vehicle ( Fig. 2A, B) . However, the difference was not statistically significant. Rapamycin also caused a small (but also not statistically significant) decrease in the basal rate of bile flow ( Fig. 2A) . The values for baseline bile flow (μl/ min.g), bile flow in the last 20 min of reperfusion (μl/min.g), initial rate of bile flow recovery (μl/min.g per minute), and area under the bile flow recovery curve (μl/g) for livers pre-treated with vehicle were 1.45 ± 0.15, 1.09 ± 0.16, 0.098 ± 0.037 and 37.4 ± 6.0, respectively, for livers pre-treated with vehicle, and 1.25 ± 0.06, 0.73 ± 0.10 (P < 0.05, Student's t-test, one tailed), 0.044 ± 0.014, and 23.0 ± 4.1 (P < 0.05), respectively, for livers pre-treated with rapamycin (means ± S.E.M. (n = 4 (vehicle) and 6 (rapamycin))). In rats treated with rapamycin (i. v. injection), the blood concentration of rapamycin was 11 ± 3 nM (Mean ± S.E.M., n = 5).
To further analyze the effect of rapamycin on the bile flow recovery after ischemia, a correlation analysis was performed to compare the rates of bile flow recovery in individual rats with the measured blood rapamycin concentration. A skewed distribution was obtained with a Pearson correlation coefficient of 0.22, indicating a low level of correlation (Fig. 2C ). Even at the highest blood concentration of rapamycin achieved, there was little inhibition of the rate of bile flow recovery.
To test whether acute administration of rapamycin inhibits the basal rate of bile flow, rapamycin was administered to the vena cava of shamoperated rats and the effect on bile flow determined (shown schematically in Fig. 1A, C) . No inhibition of the basal rate of bile flow was detected within a 40 min period following rapamycin administration (Fig. 2 D) .
Effects of rapamycin on the expression of bile acid transporters in the liver
To determine whether pre-treatment of the liver with rapamycin alters the expression of bile acid transporters, we used the same protocol for 24 h pre-treatment with rapamycin as in our previous studies (Kist et al., 2012) . Rapamycin (4 mg/kg body weight) or vehicle was administered to rats by i.p. injection 24 h before subjecting the liver to segmental hepatic ischemia and reperfusion (shown schematically in Fig. 1A, D) . The concentration of rapamycin in the blood at the end of the 24 h period was 20 ± 4 nM (mean ± S.E.M., n = 4). Samples were collected from each liver lobe, and the relative expression of mRNA encoding the bile acid transporters Ntcp, Oatp 1 and 2, Mrp2 and Bsep was determined using qPCR. Ntcp, Oatp 1 and Oatp2 are the principal transporters responsible for the uptake of bile salts from the portal blood to hepatocytes across the sinusoidal and basolateral membranes (sinusoidal transporters), while Mrp2 and Bsep are the principle transporters which mediate the transport of bile salts from hepatocytes Table 1 Sequences of primers and probes used to measure the expression of mRNA encoding bile acid transporters. F. Afroz et al. European Journal of Pharmacology 838 (2018) 91-106 to the bile canaliculus across the canalicular membrane (canalicular transporters) (Boyer, 2013; Wolkoff, 2014) . In liver lobes pre-treated with rapamycin and subject to normal blood flow, expression of mRNA encoding each of the sinusoidal transporters Ntcp, Oatp1, and Oatp2 was reduced 2-fold, 6-fold and 3-fold, respectively, compared to that in liver lobes pre-treated with vehicle and subject to normal blood flow (Fig. 3A-C , Non IR Rapamycin compared with Non IR Vehicle). For the canalicular transporters, expression of Mrp2 mRNA was increased 7-fold by rapamycin pre-treatment, and that of Bsep mRNA was decreased 2-fold (Fig. 3D ,E Non IR Rapamycin compared with Non IR Vehicle). In liver lobes pre-treated with rapamycin and subjected to IR, expression of Ntcp, Oatp1, and Oatp2 mRNA was increased 2-fold, decreased 3-fold, and was not changed, respectively, compared to that in livers pre-treated with vehicle and subject to IR (Fig. 3A-C , IR Rapamycin compared with IR Vehicle), while that of Mrp2 and Bsep mRNA was increased 2-fold and not changed, respectively (Fig. 3D , E IR Rapamycin compared with IR Vehicle).
Ischemia reperfusion alone (in the absence of rapamycin) also altered the expression of bile acid transporters. Thus, in liver lobes pretreated with vehicle then subjected to IR, there was a small increase in the expression of Ntcp mRNA, but this was not statistically significant (Fig. 3A , IR Vehicle compared with Non IR Vehicle). Expression of Oatp1 and Oatp2 was decreased 2-fold and 2.5-fold, respectively by IR (Fig. 3B, C , IR Vehicle compared with Non IR Vehicle). In livers subject to IR, the expression of Mrp2 and Bsep mRNA was increased 2.5-fold and decreased 2-fold, respectively (Fig. 3D , E IR Vehicle compared with Non IR Vehicle).
Changes in the expression of Oatp2 and Mrp2, induced by pretreatment (i.p. injection 24 h) with rapamycin, and by subjecting the liver lobes to IR, were also observed when the expression of these proteins was determined using western blot. Western blots with antiOatp2 showed bands at 25, 50 and 75 kDa (Fig. 4A, E) . The reported size for Oatp2 on western blot is 75 kDa (Gao et al., 1999; Kakyo et al., 1999; Zhang et al., 2015) , although bands of 50 kDa (Meng et al., 2002) and 115 kDa, thought to be a glycosylated form (Rausch-Derra et al., 2001) , have also been observed. Western blots with anti-Mrp2 showed bands at 50, 100 and about 170 kDa (Fig. 4C) . The reported size for Mrp2 on western blot is 175 kDa (Zhang et al., 2015) , although 190 kDa has also been observed (Dai et al., 2015) . Pre-treatment with rapamycin caused a small decrease in the expression of the Oatp2 protein, detected as a band of 75 kDa (Gao et al., 1999; Kakyo et al., 1999; Zhang et al., 2015) (Fig. 4A and B) , and increased expression of the Mrp2 protein, detected as a band of 170 kDa (Zhang et al., 2015) (Fig. 4C and D) . In the absence of pre-treatment with rapamycin, IR caused a decrease in expression of the Oatp2 protein ( Fig. 4E and F) .
Effects of rapamycin on the expression of mRNA encoding bile acid transporters in cultured hepatocytes
The actions of rapamycin on the expression of bile acid transporters were further investigated using rat hepatocytes in primary culture in order to confirm the results obtained in vivo and to investigate doseresponse relationships. Incubation of hepatocytes with 0.1 μM rapamycin decreased the expression of mRNA encoding each of the sinusoidal bile acid transporters Ntcp, Oatp1 and Oatp2 by 3-fold, 5-fold and 3-fold, respectively, compared to the vehicle control (Fig. 5A-C) . At a concentration of 0.5 μM, rapamycin caused no change in the expression of Ntcp mRNA, decreased expression of Oatp1 mRNA by 20-fold, and decreased expression of Oatp2 mRNA by 5-fold, compared to the vehicle control. The dose-response curve for the action of rapamycin on Ntcp mRNA expression was biphasic (Fig. 6A) . At concentrations from Fig. 2 . Effects of acute administration of rapamycin on bile flow recovery following ischemia (A-C) and on the basal rate of bile flow (D). A, B) Plots of the rate of bile flow as a function of time measured in the presence or absence of rapamycin (2.5 mg/kg body weight). Rapamycin was administered by i.v. injection to the vena cava of anesthetised rats 50 min before clamping of the portal triad (shown schematically in Fig. 1A, B) . Bile flow is expressed as μl/min.g wet weight of liver (A) and as a percentage of the baseline value (B). Means ± S.E.M., n = 4 (vehicle) or 6 (rapamycin). The rates of recovery of bile flow following the initiation of reperfusion (determined for the first 10 min of reperfusion) were 0.098 ± 0.034 and 0.044 ± 0.014 μl/min g per min (means ± S.E.M., P = 0.07, Student's t-test, one tailed) for Vehicle and Rapamycin, respectively, in (A) and 6.31 ± 1.83 and 3.43 ± 1.10% units per min (P = 0.09) for Vehicle and Rapamycin, respectively in (B). C) Scatter plot of the rate of bile flow following reperfusion (bile flow recovery) as a function of the measured blood concentration of rapamycin for the individual rats in the rapamycin group in (A). Pearson correlation coefficient returned an r 2 -value of 0.232. Bile flow is expressed as a percentage of the baseline value. D) Plots of the basal rate of bile flow as a function of time for individual sham-operated (no ischemia) rats. Rats were anesthetised, the bile duct was cannulated, and bile flow measured. Rapamycin (2.5 mg/kg body weight) or vehicle was administered by i.v. injection to the inferior vena cava (shown schematically Fig. 1A, C) at the time indicted by the arrow in Panel (D). The mean blood concentration of rapamycin at the end of the experiment was 11 ± 3 nM (n = 5). Each line represents an individual rat to which either vehicle (dashed lines) or rapamycin (solid lines) was administered. zero to 0.1 μM, inhibition of Ntcp mRNA expression was observed with a concentration of rapamycin of about 0.05 μM giving half-maximal inhibition (S 0.5 ) (Fig. 6A) . At concentrations of rapamycin above 0.1 μM, the inhibition of Ntcp mRNA expression was reversed (Fig. 6A) . The dose response curve for the inhibition of Oatp1 expression by rapamycin was monophasic, with an S 0.5 of about 0.05 μM (Fig. 6B) .
In contrast to its effects on the expression of sinusoidal bile acid transporters, rapamycin at 0.1 μM induced the expression of mRNA encoding the canalicular bile acid transporters Mrp2 and Bsep by 4-and 3-fold, respectively, compared to vehicle (Fig. 5D, E) . However at 0.5 μM, no induction of Mrp2 mRNA expression, compared with vehicle, was observed with rapamycin. The increase in expression of Bsep mRNA at 0.5 μM rapamycin was about the same (2-fold) as that observed for 0.1 μM rapamycin. The dose-response curve for the actions of rapamycin on expression of Bsep mRNA was biphasic (Fig. 6C) . When the rapamycin concentration was increased from zero to about 0.1 μM an increase in Bsep mRNA expression was observed with an S 0.5 of about 0.05 μM rapamycin. However, as the rapamycin concentration was increased further, the expression of Bsep mRNA decreased. The concentration of rapamycin at which expression of Bsep mRNA was 50% of that at the peak was about 1.0 μM. Overall, the effects of rapamycin in isolated hepatocytes were similar to those for livers in vivo, with the exception of the expression of Bsep mRNA which was decreased in the liver in vivo but increased in hepatocytes in culture at 0.1 μM rapamycin. However, the dose response curve for the actions of rapamycin on Bsep expression in isolated hepatocytes, which was biphasic, showed inhibition of Bsep expression at rapamycin concentrations above 0.2 μM.
Effects of rapamycin on the expression of mRNA encoding bile acid transporters in tumorigenic H4IIE rat liver cells
For HCC patients who have not been treated by liver resection or liver transplant, but have been treated with rapamycin, tumorigenic as well as normal hepatocytes would be exposed to the drug. Therefore, we also investigated the ability of rapamycin to alter the expression of bile acid transporters in tumorigenic liver cells. For this purpose, we used the tumorigenic H4IIE rat liver cell line, which was originally derived from the rat H-35 Reuber hepatoma (Evans and Kovacs, 1977; Pitot et al., 1964; Reuber, 1961) . PCR was used to determine which of the main transporters of bile acids and other components of bile fluid is expressed in H4IIE cells. The results are summarized in Table 2 and Supplementary Fig. 1 . mRNA encoding the sinusoidal bile acid transporters Ntcp, Oatp1, and Oatp2, but not Oatp9, was detected in H4IIE cells, while mRNA encoding canalicular bile acid transporters Mdr1a, Mdr1b, Mdr2 (Mdr3/2) and Mrp2, but not Bsep or Bcp, was detected in H4IIE cells. Relative expression of mRNA encoding the sinusoidal bile acid transporters Ntcp, Oatp1 and Oatp2, assessed using qPCR, was very much lower in H4IIE cells compared to that in rat hepatocytes (Fig. 7A-C) , while for canalicular transporter Mrp2, expression in H4IIE cells was higher than that in rat hepatocytes (Fig. 7D) . Differentiation of H4IIE cells by incubation with insulin and dexamethasone for 5-10 days, as described in Section 2, did not alter the expression of mRNA encoding Ntcp or Mrp2, compared to that in undifferentiated (untreated with insulin and dexamethasone) H4IIE cells, but did increase the expression of Oatp1 and Oatp2 (Fig. 7A, D) .
The effects of rapamycin on expression of mRNA encoding bile acid transporters in H4IIE cells are shown in Fig. 8 . Rapamycin at 0.1 or 0.5 μM induced expression of sinusoidal transporters Ntcp and Oatp1, but decreased expression of Oatp2 (Fig. 8A, C, E) . Rapamycin, at 0.5 μM, also induced expression of canalicular transporter Mrp2 (Fig. 8G) . The effects of rapamycin on the expression of Ntcp, Oatp1, Oatp2, and Mrp2 mRNA in differentiated H4IIE cells were similar to those for undifferentiated H4IIE cells, except that in differentiated cells rapamycin at 0.5 μM increased, rather than decreased, Oatp2 mRNA expression.
Several transcription factors are involved in the regulation of bile acid transporter expression (Jansen, 2018; Jigorel et al., 2006; Tanaka et al., 2009; Trauner et al., 2017; Weerachayaphorn et al., 2009 Weerachayaphorn et al., , 2012 Zollner et al., 2010) . One of these, nuclear factor-E2-related factor 2 Fig. 3 . Effects of pre-treatment with rapamycin on the expression of mRNA encoding the sinusoidal bile acid transporters Ntcp (A), Oatp1 (B) and Oatp2 (C) and the canalicular transporters Mrp2 (D) and Bsep (E) in rat liver lobes subject to normal blood flow (open bars, Non IR) or to ischemia and reperfusion (solid bars, IR). Rapamycin (Rapa) (4 mg/kg body weight) or vehicle (Veh) was administered to rats by i.p. injection (shown schematically in Fig. 1A, D) . After 24 h the rat was anesthetised and the bilateral median and left lateral (superior) lobes were made ischemic for 45 min followed by reperfusion for 90 min whereas the right lateral and caudate lobes received normal blood flow. At the end of the reperfusion period, liver samples were collected from each lobe, frozen, and RNA subsequently extracted. The relative expression of mRNA encoding bile acid transporters was measured using qPCR. Results show mRNA expression (normalized to β-actin expression) and referred to the value for the vehicle non IR lobe. The values are the means ± S.E.M. (n = 4 separate livers). Degrees of significance, determined using ANOVA with post hoc contrast or Students t-test for unpaired samples, for comparison of rapamycin with vehicle for the non-ischemic (inferior) and ischemic (superior) lobes, and for comparison of vehicle IR with vehicle non-IR are * P < 0.05, ** P < 0.01, and *** P < 0.001.
(caption on next page) F. Afroz et al. European Journal of Pharmacology 838 (2018) [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] (Nrf2), is activated by rapamycin (Klempner et al., 2013; Yao et al., 2016; Zhang et al., 2016a Zhang et al., , 2016b . To evaluate the possible role of Nrf2 in the mechanism by which rapamycin alters the expression of bile acid transporters, we compared the actions of rapamycin on H4IIE cells with those of oltipraz, an established activator of Nrf2 (Weerachayaphorn et al., 2009) . For the sinusoidal transporters, oltipraz, at 50 μM, inhibited the expression of Ntcp, Oatp1 and Oatp2 mRNA (Fig. 9A, C, D) . Inhibition of the expression of Ntcp and Oatp1 mRNA was also observed at 25 μM oltipraz (Fig. 9A, C) whereas at this concentration oltipraz increased the expression of Oatp2 mRNA (Fig. 9D) . The dose response curve for oltipraz-induced inhibition of Ntcp mRNA expression was monophasic, with an S 0.5 of 50 μM (Fig. 9B) . For the canalicular transporters, oltipraz at both 25 and 50 μM increased the expression of Mrp2 mRNA, with a monophasic dose response curve and an S 0.5 of 50 μM (Fig. 9E, F) . Comparison of these results for the effects of oltipraz on the expression of bile acid transporters in H4IIE cells with those of rapamycin ( Fig. 8) indicates that, with the exception of Mrp2, at the concentrations employed, oltipraz and rapamycin had opposite effects on the expression of bile acid transporters.
Discussion
We previously found that 24 h pre-treatment of rats with rapamycin, administered by i.p. injection, inhibits both the basal rate of bile flow and bile flow recovery following liver IR (Kist et al., 2012) . The aims of this study were to investigate the roles of direct inhibition (competitive or allosteric) of bile acid transporter activity and altered expression of bile acid transporters in the mechanisms by which pre-treatment with rapamycin for 24 h inhibits bile flow in normal hepatocytes. An additional aim was to compare the effects of rapamycin on the expression of bile acid transporters in tumorigenic liver cells with those on normal hepatocytes. The main findings can be summarized as follows. In a rat Fig. 4 . Effects of pre-treatment with rapamycin (i.p. injection 24 h) and of ischemia reperfusion on expression of the sinusoidal bile acid transporter Oatp2 protein (A, B and E, F) and the canalicular transporter Mrp2 protein (C, D), assessed by western blot, in rat liver lobes subject to normal blood flow (open bars, Non IR) or to ischemia and reperfusion (solid bars, IR). Ischemia and reperfusion were conducted as described in the legend of Fig. 3 . A, C, E) Chemiluminescence images of Western blots showing Oatp2 (75 kDa) and Mrp2 (160 kDa). A section of the Stain-Free protein image of the PVDF membrane after transfer of protein from the gel to the membrane (Protein loading control) is shown as a visual loading control only. B, D, F) Results expressed as band intensity (normalized to total protein on the membrane). Means ± S.E.M. (n = 3-5 separate livers). Fig. 5 . Effects of pre-treatment with rapamycin on the expression of mRNA encoding the sinusoidal bile acid transporters Ntcp (A), Oatp1 (B) and Oatp2 (C) and the canalicular transporters Mrp2 (D) and Bsep (E) in cultured rat hepatocytes. Freshly-isolated rat hepatocytes were incubated in the presence of 0.1 or 0.5 μM rapamycin (Rapa) or with vehicle for 36 h. RNA was then isolated and the relative expression of mRNA encoding bile acid transporters was measured using qPCR. Results show mRNA expression (normalized to β-actin expression) and referred to the "no addition" control. The results are means ± S.E.M. (n = 9, 3 individual hepatocyte preparations made on separate days). Degrees of significance, determined using ANOVA with post hoc contrast or Students t-test for unpaired samples, for comparison of rapamycin with vehicle are * P < 0.05, ** P < 0.01, and *** P < 0.001. model of segmental ischemia reperfusion injury, acute administration of rapamycin to the liver by i.v. injection into the vena cava did not inhibit the basal rate of bile flow. Pre-treatment of livers or cultured hepatocytes with rapamycin for 24 or 36 h caused a large decrease in the expression of mRNA encoding the sinusoidal (influx) bile acid transporters Ntcp, Oatp1 and Oatp2, and the canalicular (efflux) transporter Bsep while increasing expression of the canalicular transporter Mrp2. In tumorigenic H4IIE rat liver cells, several bile acid transporters were either not expressed or were expressed at very low levels compared to those in rat hepatocytes. While, in H4IIE cells, rapamycin induced the expression of mRNA encoding sinusoidal Ntcp and Oatp1 and of canalicular Mrp2, it decreased the expression of sinusoidal Oatp2.
The observation that rapamycin administration by the i.v. route did not alter the basal rate of bile flow measured in the subsequent 40 min indicates that, under the conditions of the present experiments, rapamycin does not inhibit bile flow by competitive, non-competitive or allosteric inhibition of the activity of bile acid transporters. Therefore, it is unlikely that inhibition of bile acid transporter activity by binding of rapamycin to the transporter proteins is responsible for the previously observed inhibition of bile flow recovery following IR in rats pretreated for 24 h with rapamycin (Kist et al., 2012) . However, in livers pre-treated for 24 h with rapamycin and not subjected to IR, expression of mRNA encoding the three sinusoidal transporters, together with that of the canalicular transporter Bsep, was decreased. The same pattern of changes in bile acid transporter mRNA expression was observed in livers pre-treated for 24 h with rapamycin and subjected to IR, except that for livers subjected to IR expression of Ntcp was increased, rather than decreased, by rapamycin. With respect to evaluating the mechanism by which 24 h pre-treatment with rapamycin inhibits bile flow recovery in the period of reperfusion 0-60 min following ischemia, the state of expression of bile acid transporters at the beginning of the reperfusion period is likely to be the most relevant. The observation that, under these conditions, the expression of all three sinusoidal bile acid transporters is decreased suggests that lower activity of the sinusoidal bile acid transporters is principally responsible for the slower bile flow recovery observed after 24 h rapamycin pre-treatment. There is also likely some contribution of changes in expression of canalicular bile acid transporters since the expression of Bsep mRNA was decreased and that of Mrp2 increased. Expression of Mrp2 may be increased as part of the mechanism to increase the extrusion of drugs (rapamycin) from hepatocytes (Stieger and Mahdi, 2017) .
In the present study, we observed that the administration of rapamycin by the i.v. route 50 min before clamping of the portal triad caused a small inhibition of bile flow recovery, measured during a period of 40 min reperfusion following 30 min of ischemia. Moreover, in the absence of pre-treatment with rapamycin, ischemia and reperfusion altered the expression of bile acid transporters, measured at 135 min after initiation of ischemia. The latter observation indicates that changes in the expression of mRNA encoding bile acid transporters can occur within about 2 h. Therefore, in livers subject to IR where rapamycin was administered by the i.v. route 50 min before the measurement of bile flow recovery (a period 80-125 min after rapamycin administration), the observed inhibition by rapamycin of bile flow recovery is also likely due to decreased expression of sinusoidal bile acid transporters.
Other mechanisms which could also account for the inhibition of bile flow recovery during reperfusion following ischemia in livers pretreated with rapamycin include altered trafficking of bile acid transporters to the plasma membrane, inhibition of bile acid synthesis, inhibition of bile flow by increased expression of heme oxygenase-1 in hepatocytes, and altered activity of bile duct cholangiocytes (Boyer, 2013; Chen et al., 2010; Deters et al., 2004 Deters et al., , 2001 Eipel et al., 2007; Fig. 6 . Dose-response curves for the effects of rapamycin on the expression of mRNA encoding the sinusoidal bile acid transporters Ntcp (A) and Oatp1 (B) and the canalicular transporter Bsep (C) in cultured rat hepatocytes. Freshly-isolated rat hepatocytes were incubated in the presence of a given concentration of rapamycin (Rapa) or with vehicle for 36 h. RNA was then isolated and the relative expression of mRNA encoding bile acid transporters was measured using qPCR. Results show mRNA expression (normalized to β-actin expression) and referred to the "no addition" control. The results are means ± S.E.M. (n = 9, 3 individual hepatocyte preparations made on separate days). The solid lines represent lines of best fit to the experimental data. Gueguen et al., 2007; Scheingraber et al., 2009) . While these mechanisms may play some role and cannot be excluded, the present results indicate that the main mechanism involves altered expression of bile acid transporters. It is also possible that pre-treatment with rapamycin exacerbates damage to mitochondria induced by reactive oxygen species and the subsequent decrease in ATP synthesis which are caused by IR (Han et al., 2018; Martins et al., 2018) . Since the maintenance of normal bile flow in the liver is dependent on an adequate supply of ATP, damage to mitochondria would lead to a decrease in bile flow (Boyer, 2013) . However, other studies have provided evidence that pretreatment with rapamycin can protect the liver from IR injury and reduce the formation of reactive oxygen species, suggesting that exacerbation of damage to mitochondria induced by IR is unlikely to account for the observed decrease in bile flow following pre-treatment with rapamycin and IR (Kist et al., 2012; Lee et al., 2016; Martinez-Cisuelo et al., 2016) . Following the administration of rapamycin to patients, the blood concentrations of rapamycin are generally in the range of 5-10 nM (Shinke et al., 2013; Trotter, 2003) . On the basis of the dose-response curves reported here for the action of rapamycin on the expression of bile acid transporters, it can be predicted that rapamycin would decrease the expression of bile acid transporters in patients receiving ongoing treatment with this drug. Thus, decreased expression of sinusoidal bile acid transporters would be expected to cause some inhibition of bile flow in patients treated with the drug, and may contribute to some cases of rapamycin-induced cholestasis (Bramow et al., 2001; Dandel et al., 2010; Pantano et al., 2010) .
Female patients who have undergone liver surgery exhibit better Fig. 7 . Relative expression of bile acid transporters in cultured tumorigenic H4IIE rat liver cells compared to that in cultured rat hepatocytes. H4IIE cells, H4IIE cells pre-treated with insulin and dexamethasone for 5-14 days to induce differentiation, as described in Section 2, or freshly-isolated rat hepatocytes were incubated for 36 h following subculture. RNA was then isolated and the relative expression of mRNA encoding the bile acid transporters Ntcp (A), Oatp1 (B), Oatp2 (C), and Mrp2 (D) was measured using qPCR. Results show mRNA expression (normalized to β-actin expression) and referred to the undifferentiated H4IIE cells (no pre-treatment with insulin and dexamethasone). The results are means ± S.E.M. (n = 9, 3 individual hepatocyte preparations conducted on separate days, or 3 individual H4IIE cell cultures). Degrees of significance, determined using ANOVA with post hoc contrast or Students t-test for comparison of the values for hepatocytes and differentiated H4IIE cells with those of H4IIE cells, are ** P < 0.01, and *** P < 0.001. Fig. 8 . Effects of rapamycin on the expression of bile acid transporters in tumorigenic H4IIE rat liver cells. Effects of pre-treatment with rapamycin on the expression of mRNA encoding the bile acid transporters Ntcp (A, B), Oatp1 (C, D), Oatp2 (E, F) and Mrp2 (G, H) in H4IIE cells. H4IIE cells, or H4IIE cells differentiated by incubation in the presence of insulin and dexamethasone, were incubated in the presence of 0.1 or 0.5 μM rapamycin (Rapa) or with vehicle (Vehicle) for 36 h. RNA was then isolated and the relative expression of mRNA encoding a give bile acid transporter was measured using qPCR. Results show mRNA expression (normalized to β-actin expression) and referred to the "no addition" control. The results are means ± S.E.M. (n = 9, 3 separate cell incubations). Degrees of significance, determined using ANOVA with post hoc contrast, or Students t-test for comparison of rapamycin with vehicle are * P < 0.05, ** P < 0.01 and *** P < 0.001.
survival and less hepatic damage from IR injury than male patients (Harada et al., 2001) . We have previously shown that, in a rat model of segmental ischemia reperfusion, bile flow recovery following ischemia is faster in females than in males, although estrogen receptors appear to play only a limited role in this difference (de Vries et al., 2013) . Future studies of the effects of rapamycin pre-treatment on bile flow recovery following liver ischemia in female rats would be valuable. The present results show that the expression of several bile acid transporters is much lower in tumorigenic liver cells compared to normal hepatocytes. Decreased expression of some bile acid transporters in tumorigenic liver cells has been previously reported (von Dippe and Levy, 1990) . These results suggest that the contribution by tumorigenic liver cells to total liver bile flow is likely to be small. Moreover, any effect of rapamycin in altering the expression of bile acid transporters in tumorigenic liver tissue is also likely to be small. The observations that several bile acid transporters were expressed at very low levels in tumorigenic H4IIE rat liver cells compared to hepatocytes and that the effects of rapamycin on the expression of some bile acid transporters in H4IIE cells were opposite to those observed for hepatocytes suggest that immortalized liver cells, such as H4IIE cells, may not be a good model for studying some aspects of the regulation of the expression of bile acid transporters.
Several different transcription factors, including farnesyl × receptor, retinoid × receptor, small heterodimer partner, hepatic nuclear factor 4α, glucocorticoid receptor, constitutive androstane receptor, pregnane × receptor, and Nrf2 are involved in the regulation by extracellular and intracellular signals of the expression of bile acid transporters (Jansen, 2018; Jigorel et al., 2006; Tanaka et al., 2009; Trauner et al., 2017; Weerachayaphorn et al., 2009 Weerachayaphorn et al., , 2012 Zollner et al., 2010) . Nrf2, is activated by rapamycin. The activation pathway is thought to involve rapamycin-induced inhibition of mTOR1 which leads to the inhibition of S6 kinase, indirect activation of the phosphoinositide 3-kinase (PI3K)/ serine/threonine kinase protein kinase B (AKT) pathway and the activation of Nrf2 (Klempner et al., 2013; Yao et al., 2016; Zhang et al., 2016a Zhang et al., , 2016b . To test the involvement of Nrf2, we employed oltipraz, an established activator of Nrf2 (Weerachayaphorn et al., 2009 ). However, in H4IIE cells incubated under the conditions employed, the effects of oltipraz on expression of bile acid transporters were opposite to those of rapamycin, with the exception of induction of the expression of Bsep mRNA. Therefore, while Nrf2 may mediate some of the effects of rapamycin on bile acid transporters observed in this study, rapamycin-induced changes in bile acid transporter expression are likely mediated by several different transcription factors, of which Nrf2 may be one. Differential changes in the activities of two or more transcription factors may explain the biphasic dose response curves for the action of rapamycin on the expression of Ntcp and Bsep, and the opposite effects which rapamycin has on the expression of Ntcp and Oatp1 mRNA in H4IIE cells compared to hepatocytes. Future studies, in which the expression of a given transcription factor is modified using siRNA or overexpression, are warranted in order to define the transcription factors mediating the actions of rapamycin on the expression of bile acid transporters.
Conclusion
It is concluded that the principal mechanism involved in the inhibition by rapamycin of bile flow recovery following liver ischemia is inhibition of the expression of sinusoidal bile acid transporters. Moreover, in tumorigenic liver tissue the contribution of tumorigenic liver cells to total liver bile flow is likely to be small and is unlikely to be greatly affected by rapamycin. The intracellular mechanisms by which rapamycin alters the expression of bile acid transporters likely involve changes in the activity and actions of several transcription factors, one of which is Nrf2. Fig. 9 . Effects of oltipraz on the expression of bile acid transporters in tumorigenic H4IIE rat liver cells. (A, C, D, E) Effects of pre-treatment with oltipraz (Olti) (25 or 50 μM) on the expression of mRNA encoding the bile acid transporters Ntcp (A), Oatp1 (C), Oatp2 (D) and Mrp2 (E). (B, F) Dose-response curves for the effects of oltipraz on the expression of mRNA encoding Ntcp (B) and Mrp2 (F). Cells were incubated in the presence of oltipraz or vehicle for 36 h. RNA was then isolated and the relative expression of mRNA encoding a given bile acid transporter was measured using qPCR. Results show mRNA expression (normalized to β-actin expression) and referred to the "no addition" control. The results are means ± S.E.M. (n = 9, 3 separate cell incubations). Degrees of significance in (A, C, D, E), determined using ANOVA with post hoc contrast or Students t-test for unpaired samples, for comparison of rapamycin with vehicle are * P < 0.05, ** P < 0.01 and *** P < 0.001. The solid lines represent lines of best fit to the experimental data.
